Full text is available at the source.
Safety and immune response of a smaller matching booster dose of the Pfizer COVID-19 vaccine in a controlled follow-up trial
Updated
Abstract
Reduced-dose primo-vaccination against COVID-19 demonstrated safety and immunogenicity.
- Fractional booster dosing may maintain strong immune response and protection.
- Reduced doses could result in fewer side effects, enhancing acceptability.
- This approach may help conserve vaccine supplies.
Simplified
mRNA Technology